Home
/
TherapeuticsMD, Inc.
/
Financials
/
Quarterly
TherapeuticsMD, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that TherapeuticsMD, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2011
Sep 30, 2011
$2.1K
Nov 7, 2011
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2023
Sep 30, 2023
($53.0K)
Nov 14, 2023
Q2
2023
Jun 30, 2023
$437.0K
Aug 14, 2023
Q1
2023
Mar 31, 2023
$416.0K
May 15, 2023
Q3
2023
Sep 30, 2022
$354.0K
Nov 14, 2023
Q2
2023
Jun 30, 2022
$348.0K
Aug 14, 2023
Q1
2023
Mar 31, 2022
$695.0K
May 15, 2023
Q3
2022
Sep 30, 2021
$25.41M
Nov 14, 2022
Q2
2022
Jun 30, 2021
$23.00M
Aug 15, 2022
Q1
2022
Mar 31, 2021
$19.87M
May 16, 2022
Q3
2021
Sep 30, 2020
$19.34M
Nov 12, 2021
Q2
2021
Jun 30, 2020
$10.70M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$12.25M
May 6, 2021
Q3
2020
Sep 30, 2019
$23.72M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$6.08M
Aug 7, 2020
Q1
2020
Mar 31, 2019
$3.95M
May 6, 2020
Q3
2019
Sep 30, 2018
$3.47M
Nov 8, 2019
Q2
2019
Jun 30, 2018
$3.76M
Aug 9, 2019
Q1
2019
Mar 31, 2018
$3.77M
May 8, 2019
Q3
2018
Sep 30, 2017
$4.42M
Nov 8, 2018
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2018
Jun 30, 2018
$3.76M
Jul 30, 2018
Q1
2018
Mar 31, 2018
$3.77M
May 7, 2018
Q3
2017
Sep 30, 2017
$4.42M
Nov 7, 2017
Q2
2017
Jun 30, 2017
$4.25M
Aug 3, 2017
Q1
2017
Mar 31, 2017
$3.99M
May 3, 2017
Q3
2016
Sep 30, 2016
$5.54M
Nov 4, 2016
Q2
2016
Jun 30, 2016
$4.40M
Aug 5, 2016
Q1
2016
Mar 31, 2016
$4.93M
May 5, 2016
Q3
2015
Sep 30, 2015
$5.19M
Nov 5, 2015
Q2
2015
Jun 30, 2015
$4.85M
Aug 7, 2015
Q1
2015
Mar 31, 2015
$4.48M
May 7, 2015
Q3
2014
Sep 30, 2014
$4.19M
Nov 7, 2014
Q2
2014
Jun 30, 2014
$3.75M
Aug 7, 2014
Q1
2014
Mar 31, 2014
$2.83M
May 7, 2014
Q3
2013
Sep 30, 2013
$2.29M
Nov 5, 2013
Q2
2013
Jun 30, 2013
$2.08M
Aug 7, 2013
Q1
2013
Mar 31, 2013
$1.54M
May 10, 2013
Q3
2012
Sep 30, 2012
$1.04M
Nov 13, 2012
Q2
2012
Jun 30, 2012
$819.2K
Aug 9, 2012
Q1
2012
Mar 31, 2012
$721.7K
May 11, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$152.0K
Nov 12, 2025
Q3
2025
Jun 30, 2025
$551.0K
Nov 12, 2025
Q2
2025
Jun 30, 2025
$551.0K
Aug 12, 2025
Q1
2025
Mar 31, 2025
($653.0K)
May 13, 2025
Q2
2025
Mar 31, 2025
($653.0K)
Aug 12, 2025
Q3
2025
Mar 31, 2025
($653.0K)
Nov 12, 2025
Q3
2025
Sep 30, 2024
($609.0K)
Nov 12, 2025
Q3
2025
Jun 30, 2024
($1.09M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($1.09M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($734.0K)
May 13, 2025
Q3
2025
Mar 31, 2024
($734.0K)
Nov 12, 2025
Q2
2025
Mar 31, 2024
($734.0K)
Aug 12, 2025
Q3
2023
Sep 30, 2023
($3.38M)
Nov 14, 2023
Q2
2024
Jun 30, 2023
($2.41M)
Aug 12, 2024
Q3
2023
Jun 30, 2023
($2.41M)
Nov 14, 2023
Q3
2023
Mar 31, 2023
($3.60M)
Nov 14, 2023
Q1
2023
Mar 31, 2023
($3.60M)
May 15, 2023
Q2
2024
Mar 31, 2023
($3.60M)
Aug 12, 2024
Q3
2023
Sep 30, 2022
($28.97M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
$112.28M
Aug 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($862.0K)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($695.0K)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($871.0K)
May 13, 2025
Q3
2025
Sep 30, 2024
($1.13M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($2.79M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($1.14M)
May 13, 2025
Q3
2023
Sep 30, 2023
($1.77M)
Nov 14, 2023
Q2
2024
Jun 30, 2023
($2.47M)
Aug 12, 2024
Q1
2023
Mar 31, 2023
($2.67M)
May 15, 2023
Q3
2023
Sep 30, 2022
($14.52M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($14.86M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($17.88M)
May 15, 2023
Q3
2022
Sep 30, 2021
($39.92M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($35.18M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($29.28M)
May 16, 2022
Q3
2021
Sep 30, 2020
($24.97M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($45.04M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($50.92M)
May 6, 2021
Q3
2020
Sep 30, 2019
($27.07M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($41.64M)
Aug 7, 2020